Portfolio

LSP 7

Investments range between EUR 30 million and EUR 60 million

LSP 7 seeks to invest in early-to-late-stage life sciences companies, developing novel and ground-breaking new medicines and technologies that provide solutions to unmet medical needs. LSP 7’s geographical focus is primarily Europe and occasionally the US.

LSP Advisory B.V.
Johannes Vermeerplein 9
1071 DV Amsterdam, the Netherlands

Company Registration Number: 34296447

LSP Advisory B.V. is an alternative investment fund manager authorized and regulated in accordance with laws of the Netherlands.

Fast facts

  • Status
    Active
  • Launch
    2021
  • Size
    EUR 1 bn
  • SFDR classification
    Art. 8

Investment advisory committee

  • Chairperson
    Prof. dr A. Pijpers
  • Ariceum Therapeutics
  • Egle Therapeutics
  • Evommune
  • HotSpot Therapeutics
  • MinervaX
  • Shinobi Therapeutics
  • Agomab Therapeutics